Free Trial

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

+0.37 (+0.96%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
357,750 shs
Average Volume
429,091 shs
Market Capitalization
$2.49 billion
P/E Ratio
Dividend Yield
Price Target

MoonLake Immunotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
90.8% Upside
$74.46 Price Target
Short Interest
14.00% of Float Sold Short
Dividend Strength
News Sentiment
0.46mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$5.34 M Sold Last Quarter
Proj. Earnings Growth
From ($1.16) to ($1.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.58 out of 5 stars

Medical Sector

452nd out of 921 stocks

Pharmaceutical Preparations Industry

197th out of 416 stocks

MLTX stock logo

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MLTX Stock Price History

MLTX Stock News Headlines

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 4.8%
MLTX Aug 2024 80.000 call
MLTX May 2024 60.000 call
MLTX Apr 2024 40.000 put
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$8.15 per share


Free Float
Market Cap
$2.47 billion
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

MLTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price target for 2024?

12 Wall Street research analysts have issued 1-year price objectives for MoonLake Immunotherapeutics' stock. Their MLTX share price targets range from $56.00 to $100.00. On average, they anticipate the company's stock price to reach $74.46 in the next year. This suggests a possible upside of 90.8% from the stock's current price.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2024?

MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of the year. Since then, MLTX shares have decreased by 35.4% and is now trading at $39.03.
View the best growth stocks for 2024 here

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our MLTX earnings forecast

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) released its earnings results on Sunday, May, 12th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03.

What ETFs hold MoonLake Immunotherapeutics' stock?
Who are MoonLake Immunotherapeutics' major shareholders?

MoonLake Immunotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.34%), Westfield Capital Management Co. LP (1.43%), Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.36%), TimesSquare Capital Management LLC (0.33%), Decheng Capital LLC (0.26%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Kristian Reich and Matthias Bodenstedt.
View institutional ownership trends

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLTX) was last updated on 5/21/2024 by Staff

From Our Partners